$57.92
+0.35
(+0.61%)▲
0.9%
Downside
Day's Volatility :3.8%
Upside
2.93%
35.17%
Downside
52 Weeks Volatility :58.78%
Upside
36.42%
Period | Crispr Therapeutics Ag | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.79% | 6.5% | 0.0% |
6 Months | -5.64% | 7.1% | 0.0% |
1 Year | 0.51% | 9.8% | 0.0% |
3 Years | -51.71% | 14.2% | -20.2% |
Market Capitalization | 4.8B |
Book Value | $24.56 |
Earnings Per Share (EPS) | -2.7 |
PEG Ratio | -0.21 |
Wall Street Target Price | 84.29 |
Profit Margin | -79.92% |
Operating Margin TTM | -27894.25% |
Return On Assets TTM | -7.97% |
Return On Equity TTM | -11.02% |
Revenue TTM | 271.7M |
Revenue Per Share TTM | 3.4 |
Quarterly Revenue Growth YOY | -99.5% |
Gross Profit TTM | -570.7M |
EBITDA | -279.0M |
Diluted Eps TTM | -2.7 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.63 |
EPS Estimate Next Year | -4.54 |
EPS Estimate Current Quarter | -1.33 |
EPS Estimate Next Quarter | -1.58 |
What analysts predicted
Upside of 45.53%
Sell
Neutral
Buy
Crispr Therapeutics Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Crispr Therapeutics Ag | 1.66% | -5.64% | 0.51% | -51.71% | 10.88% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Crispr Therapeutics Ag | 13.4 | NA | -0.21 | -5.63 | -0.11 | -0.08 | NA | 24.56 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Crispr Therapeutics Ag | Buy | $4.8B | 10.88% | 13.4 | -79.92% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Crispr Therapeutics Ag
Revenue is down for the last 2 quarters, 200.0M → 504.0K (in $), with an average decrease of 99.8% per quarter
Netprofit is down for the last 2 quarters, 89.34M → -116.59M (in $), with an average decrease of 230.5% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 61.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 238.2%
ARK Investment Management LLC
Capital Research & Mgmt Co - Division 3
Sumitomo Mitsui Trust Holdings Inc
Nikko Asset Management Americas Inc
T. Rowe Price Investment Management,Inc.
BlackRock Inc
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Organization | Crispr Therapeutics Ag |
Employees | 407 |
CEO | Dr. Samarth Kulkarni Ph.D. |
Industry | Health Technology |
Outfront Media Inc.
$57.92
+0.61%
Blackrock Short Duration Bond Etf
$57.92
+0.61%
Moog Inc
$57.92
+0.61%
Edgio Inc.
$57.92
+0.61%
Invesco S&p 500 Momentum Etf
$57.92
+0.61%
Silicon Laboratories Inc
$57.92
+0.61%
Helmerich & Payne, Inc.
$57.92
+0.61%
Crane Nxt Co
$57.92
+0.61%
Liberty Global Plc - Class C Shares
$57.92
+0.61%